Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s stock price dropped 5.4% during mid-day trading on Friday . The company traded as low as $3.75 and last traded at $3.85, approximately 1,356,400 shares traded hands during mid-day trading. An increase of 5% from the average daily volume of 1,290,548 shares. The stock had previously closed at $4.07.
A number of research firms have weighed in on LXRX. Wedbush restated a “buy” rating and issued a $17.00 price target on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. ValuEngine upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price target for the company from $3.00 to $4.00 in a research note on Friday, November 8th. Finally, Gabelli upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $6.45.
The company has a debt-to-equity ratio of 1.42, a current ratio of 8.11 and a quick ratio of 8.01. The company has a market capitalization of $387.89 million, a price-to-earnings ratio of -3.38 and a beta of 0.95. The stock has a 50 day simple moving average of $3.60 and a two-hundred day simple moving average of $4.06.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The company had revenue of $294.45 million for the quarter, compared to analysts’ expectations of $12.00 million. During the same period last year, the firm earned ($0.26) earnings per share. Lexicon Pharmaceuticals’s quarterly revenue was up 4124.5% on a year-over-year basis. Equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post 0.93 EPS for the current year.
In other news, Director Christopher J. Sobecki bought 99,249 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were acquired at an average price of $2.41 per share, for a total transaction of $239,190.09. Following the completion of the transaction, the director now owns 13,645 shares of the company’s stock, valued at $32,884.45. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Lonnel Coats bought 50,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $3.13 per share, for a total transaction of $156,500.00. Following the transaction, the chief executive officer now directly owns 127,639 shares of the company’s stock, valued at approximately $399,510.07. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 178,749 shares of company stock worth $474,560. 6.40% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of LXRX. Commonwealth Equity Services LLC increased its position in shares of Lexicon Pharmaceuticals by 40.5% during the third quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 4,746 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth about $92,000. Voloridge Investment Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth about $105,000. Quantitative Systematic Strategies LLC increased its position in shares of Lexicon Pharmaceuticals by 67.2% during the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 8,302 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Lexicon Pharmaceuticals during the third quarter worth about $202,000. Institutional investors and hedge funds own 98.78% of the company’s stock.
Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: Blue-Chip Stocks
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.